menu search

Mineralys therapeutics presents positive lorundrostat results from the phase 2 target-htn trial at acc.23/wcc

lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontroll...

March 4, 2023, 9:30 pm


Search within

Pages Search Results: